Pan-European Non-Interventional study to access Vildagliptin safety outcomes under real world conditions.
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 26 Aug 2018 Results assessing the hepatic safety of vildagliptin in patients with with type 2 diabetes (n=20973), presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 30 Aug 2017 "Incidence rate of pancreatic cancer' was added as an exploratory safety event in a protocol amendment.